应用Markov模型对桉柠蒎肠溶软胶囊治疗稳定期慢性阻塞性肺疾病的药物经济学评价

Pharmacoeconomic Evaluation of An’ningpai Soft Capsule Using Markov Model for Patients with Stable Chronic Obstructive Pulmonary Disease (COPD)

目的评估桉柠蒎肠溶软胶囊、乙酰半胱氨酸及盐酸氨溴索治疗稳定期慢性阻塞性肺疾病(chronicobstructive pulmonary disease, COPD)的经济学。方法基于临床试验数据,从医疗保健系统角度,采用Markov模型进行药物经济学评价。结果根据Markov模型队列模拟结果,在为期3年的疾病进展后,桉柠蒎肠溶软胶囊与乙酰半胱氨酸、盐酸氨溴索方案比较的增量成本-效用比分别为-4 394 660元/QLAYs和-1 517 480元/QLAYs。结论桉柠蒎肠溶软胶囊能改善气管黏膜纤毛运动,促进呼吸道腺体分泌,并使黏液移动速度增加,有助痰液排出。桉柠蒎肠溶软胶囊方案成本最低,产出最高,具有药物经济学优势。

Objective To evaluate the economic value of An’ningpai soft capsule,acetylcysteine and ambroxol hydrochloride in the treatment of stable COPD.Methods Based on the clinical trial data,Markov model was used to evaluate the cost utility of An’ningpai soft capsule from the perspective of medical care system.Results According to the results of Markov model cohort simulation,after 3 years of disease progression,the incremental cost-effectiveness ratios of An’ningpai soft capsule,acetylcysteine and ambroxol hydrochloride solutions were-4394660 yuan/QLAY and-1517480 yuan/QLAY,respectively.Conclusion An’ningpai soft capsule can improve the ciliary movement of trachea mucosa,promote the secretion of respiratory glands,increase the speed of mucus movement,and facilitate the discharge of sputum.The An’ningpai soft capsule has the lowest cost and the highest output,with absolute advantage in pharmacoeconomics.